2025
Tumefactive and longitudinally extensive myelitis: A rare presentation of multiple sclerosis?
Morehead A, Flanagan E, Solomon A. Tumefactive and longitudinally extensive myelitis: A rare presentation of multiple sclerosis? Neuroimmunology Reports 2025, 7: 100257. DOI: 10.1016/j.nerep.2025.100257.Peer-Reviewed Original ResearchSpinal cord demyelinationMultiple sclerosisCervical spinal cord lesionLongitudinally extensive myelitisPresentation of multiple sclerosisTumefactive demyelinating lesionsRare presentation of multiple sclerosisTherapeutic decision-makingRelapsing-remitting MSSpinal cord lesionsRare presentationClinical courseCord lesionsPrognostic challengesLongitudinal followDemyelinationLesionsSclerosisUnmet needsRelapseMyelitisPatientsFollow
2024
Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients
Mao-Draayer Y, Bar-Or A, Balashov K, Foley J, Smoot K, Longbrake E, Robertson D, Mendoza J, Lewin J, Everage N, Božin I, Lyons J, Mokliatchouk O, Bame E, Giuliani F. Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients. Advances In Therapy 2024, 42: 395-412. PMID: 39570545, PMCID: PMC11782338, DOI: 10.1007/s12325-024-03047-w.Peer-Reviewed Original ResearchAbsolute lymphocyte countRelapsing-remitting MSEffect of dimethyl fumarateAnnualized relapse rateDisease-modifying therapiesAdverse eventsDimethyl fumarateCD8+ T cell compartmentMultiple sclerosisOlder patientsMedian absolute lymphocyte countOral disease-modifying therapyTreated with dimethyl fumarateSafety outcomesTreating relapsing MST cell compartmentPhase 3 studyResponse to disease-modifying therapiesIncidence of SAEsLymphocyte subset changesReal-world safetyTreatment discontinuationCD4+Immunophenotypic changesRelapse rateSiponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways
Gurrea-Rubio M, Wang Q, Mills E, Wu Q, Pitt D, Tsou P, Fox D, Mao-Draayer Y. Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways. International Journal Of Molecular Sciences 2024, 25: 2454. PMID: 38473703, PMCID: PMC10931690, DOI: 10.3390/ijms25052454.Peer-Reviewed Original ResearchConceptsSecondary progressive MSRelapsing-remitting MSCentral nervous systemMultiple sclerosisProgressive MSModulator of sphingosine-1-phosphateCytokine tumor necrosis factor-alphaEffects of siponimodTumor necrosis factor-alphaHeterogeneous clinical courseBouts of inflammationNeuroprotective effectsPreclinical animal modelsAutoimmune demyelinating diseaseNecrosis factor-alphaMitochondrial oxidative phosphorylationHuman induced pluripotent stem cell (iPSC)-derived neuronsSphingosine-1-PhosphateCytokine Signaling PathwaysClinical courseLive cell analysisProgressive diseaseOral treatmentMitochondrial pathwayFactor-alpha
2023
TMEM106B Puncta Is Increased in Multiple Sclerosis Plaques, and Reduced Protein in Mice Results in Delayed Lipid Clearance Following CNS Injury
Shafit-Zagardo B, Sidoli S, Goldman J, DuBois J, Corboy J, Strittmatter S, Guzik H, Edema U, Arackal A, Botbol Y, Merheb E, Nagra R, Graff S. TMEM106B Puncta Is Increased in Multiple Sclerosis Plaques, and Reduced Protein in Mice Results in Delayed Lipid Clearance Following CNS Injury. Cells 2023, 12: 1734. PMID: 37443768, PMCID: PMC10340176, DOI: 10.3390/cells12131734.Peer-Reviewed Original ResearchConceptsAxonal damageMultiple sclerosisRelapsing-remitting multiple sclerosisHypomorphic miceExperimental autoimmune encephalomyelitisRelapsing-remitting MSNormal-appearing white matterMultiple sclerosis plaquesWhite matter plaquesNon-neurologic controlsWild-type miceBrains of individualsLipid droplet accumulationAutoimmune encephalomyelitisMyelin oligodendrocyteCNS injuryLipid clearanceSpinal cordNeuronal integrityTransmembrane protein 106BWhite matterAlzheimer's diseaseMice resultsDroplet accumulationPlaques
2022
Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions
Zinger N, Ponath G, Sweeney E, Nguyen TD, Lo CH, Diaz I, Dimov A, Teng L, Zexter L, Comunale J, Wang Y, Pitt D, Gauthier SA. Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions. Neurology Neuroimmunology & Neuroinflammation 2022, 9: e1138. PMID: 35046083, PMCID: PMC8771666, DOI: 10.1212/nxi.0000000000001138.Peer-Reviewed Original ResearchConceptsChronic active lesionsGlatiramer acetateRim lesionsHuman microgliaDimethyl fumarateMultiple sclerosisActive lesionsChronic active multiple sclerosis lesionsEffects of DMFActive multiple sclerosis lesionsClass III evidenceMarkers of inflammationRelapsing-remitting MSRetrospective observational studyQuantitative susceptibility mappingMultiple sclerosis lesionsActivation stateTreatment-induced changesMRI quantitative susceptibility mappingMicroglial activityGlial activityInflammatory activationMicroglial cellsObservational studyMS lesions
2020
Covarying patterns of white matter lesions and cortical atrophy predict progression in early MS
Muthuraman M, Fleischer V, Kroth J, Ciolac D, Radetz A, Koirala N, Gonzalez-Escamilla G, Wiendl H, Meuth S, Zipp F, Groppa S. Covarying patterns of white matter lesions and cortical atrophy predict progression in early MS. Neurology Neuroimmunology & Neuroinflammation 2020, 7: e681. PMID: 32024782, PMCID: PMC7051213, DOI: 10.1212/nxi.0000000000000681.Peer-Reviewed Original ResearchConceptsCortical atrophyDisability progressionLesion distributionWM lesionsEarly relapsing-remitting MSShort-term disability progressionWhite matter lesion distributionDisability Status Scale scoreRapid clinical deteriorationRelapsing-remitting MSStatus Scale scoreWhite matter lesionsIndividual patient outcomesLeft-lateralized patternClinical worseningClinical deteriorationClinical disabilityFunctional disabilityStudy cohortMatter lesionsEarly MSPatient outcomesHigh riskIndependent cohortSecond cohort
2019
Longitudinal cortical network reorganization in early relapsing–remitting multiple sclerosis
Fleischer V, Koirala N, Droby A, Gracien R, Deichmann R, Ziemann U, Meuth S, Muthuraman M, Zipp F, Groppa S. Longitudinal cortical network reorganization in early relapsing–remitting multiple sclerosis. Therapeutic Advances In Neurological Disorders 2019, 12: 1756286419838673. PMID: 31040880, PMCID: PMC6482642, DOI: 10.1177/1756286419838673.Peer-Reviewed Original ResearchRelapsing-remitting MSEarly relapsing-remitting MSHealthy controlsDisease activityEarly relapsing-remitting multiple sclerosisLongitudinal brain volume changesRelapsing-remitting multiple sclerosisCortical atrophy patternsStructural cortical networksPatients' disease activityNetwork reorganizationBrain volume changesClinical disease manifestationsDetectable atrophyMultiple sclerosisAtrophy patternsDisease manifestationsAtrophy measurementsCortical responsesGray matter networksBrain functionPatientsT MRICortical networksGraph theoretical analysis
2010
Elevated Intrathecal Myelin Oligodendrocyte Glycoprotein Antibodies in Multiple Sclerosis
Klawiter EC, Piccio L, Lyons JA, Mikesell R, O’Connor K, Cross AH. Elevated Intrathecal Myelin Oligodendrocyte Glycoprotein Antibodies in Multiple Sclerosis. JAMA Neurology 2010, 67: 1102-1108. PMID: 20837855, PMCID: PMC3051403, DOI: 10.1001/archneurol.2010.197.Peer-Reviewed Original ResearchConceptsMultiple sclerosisMyelin oligodendrocyte glycoproteinCerebrospinal fluidClinical disabilityMS patientsCSF markersAntibody productionForms of MSProspective case-controlled seriesMyelin oligodendrocyte glycoprotein antibodyDiagnosis of MSImmunoglobulin G indexNoninflammatory neurologic diseasesRoutine CSF testingProgressive multiple sclerosisAcademic referral centerRelapsing-remitting MSRadiographic outcome measuresMagnetic resonance metricsCase-control seriesReferral centerAlbumin levelsIgG indexCSF testingGlycoprotein antibodies
2008
Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells
De Jager PL, Rossin E, Pyne S, Tamayo P, Ottoboni L, Viglietta V, Weiner M, Soler D, Izmailova E, Faron-Yowe L, O’Brien C, Freeman S, Granados S, Parker A, Roubenoff R, Mesirov JP, Khoury SJ, Hafler DA, Weiner HL. Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain 2008, 131: 1701-1711. PMID: 18567923, PMCID: PMC2730047, DOI: 10.1093/brain/awn118.Peer-Reviewed Original ResearchConceptsRelapsing-remitting MSImmunological profileRRMS subjectsPeripheral bloodUntreated subjectsNatural killer cell profileComprehensive Longitudinal InvestigationAbsence of treatmentCell surface markersCIS subjectsDemyelinating diseaseDemyelination syndromeWomen's HospitalHealthy controlsCytometric profilingCell profilesMonoclonal antibodiesExtension phaseFresh bloodBiomarker discovery effortsDistinct subsetsBloodCell populationsGating strategyHospital
2005
Association between peripheral IFN-γ producing CD8+ T-cells and disability score in relapsing-remitting multiple sclerosis
Sepulcre J, Sanchez-Ibarrola A, Moreno C, de Castro P. Association between peripheral IFN-γ producing CD8+ T-cells and disability score in relapsing-remitting multiple sclerosis. Cytokine 2005, 32: 111-116. PMID: 16246570, DOI: 10.1016/j.cyto.2005.08.005.Peer-Reviewed Original ResearchConceptsCD8+ T cellsRelapsing-remitting MST-cell phenotypeCD8+ lymphocytesDisability scoresIFN-gammaT cellsMultiple sclerosisPeripheral blood T-cell phenotypesPatients treated with interferon-betaHealthy controlsAssociated with disability scoresBlood T-cell phenotypesPeripheral T-cell phenotypePercentage of IFN-gammaEffects of immunomodulatory treatmentsIL-4 producing CD4Decrease of IFN-gammaRelapsing-remitting MS patientsRelapsing-remitting multiple sclerosisPathogenesis of multiple sclerosisCD4+ lymphocytesT cell populationsPresence of IFN-gammaPro-inflammatory profile
2001
Decreases in Interleukin-4 Secretion by Invariant CD4−CD8−Vα24JαQ T Cells in Peripheral Blood of Patients with Relapsing–Remitting Multiple Sclerosis
Gausling R, Trollmo C, Hafler D. Decreases in Interleukin-4 Secretion by Invariant CD4−CD8−Vα24JαQ T Cells in Peripheral Blood of Patients with Relapsing–Remitting Multiple Sclerosis. Clinical Immunology 2001, 98: 11-17. PMID: 11141321, DOI: 10.1006/clim.2000.4942.Peer-Reviewed Original ResearchConceptsRelapsing-remitting multiple sclerosisT cell receptorIFN-gamma secretionMultiple sclerosisT cell clonesT cellsCytokine profilePeripheral bloodIL-4Cell clonesProgressive multiple sclerosisRR-MS patientsCytokine secretion patternsRelapsing-remitting MSInterleukin-4 secretionT cell functionalityCytokine secretionHealthy controlsSecretion patternPatientsCP-MSImmune systemControl individualsCell receptorSecretion
1995
Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis.
Balashov KE, Khoury SJ, Hafler DA, Weiner HL. Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. Journal Of Clinical Investigation 1995, 95: 2711-2719. PMID: 7769110, PMCID: PMC295954, DOI: 10.1172/jci117973.Peer-Reviewed Original ResearchConceptsAutologous mixed lymphocyte reactionProgressive multiple sclerosisChronic progressive multiple sclerosisInduction of CD8Tact cellsMultiple sclerosisT cellsHuman CD8Suppressive propertiesAutologous T cellsRelapsing-remitting MST cell responsesHuman autoimmune diseasesMixed lymphocyte reactionGM-CSF antibodySuppressive CD8Autologous antigenLymphocyte reactionAutoimmune diseasesBeta antibodyGamma antibodyCD8Proliferative responseSpecific cytokinesNormal controls
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply